Tonix Pharma Shares Drop 11% After Covid Treatment Trial Misses Endpoint

By Chris Wack

Tonix Pharmaceuticals shares were down 11% at 90 cents after the company said topline results from its Phase 2 proof-of-concept study of TNX-102 SL 5.6 mg for the management of fibromyalgia-type Long Covid missed its primary endpoint.

The stock hit its 52-week low of $1.22 on Sept. 1, and is down 93% in the past 12 months.

…